Sartorius_May21_NeutAntiMakingTheir - 3




n the last couple of years, there has been heightened interest
in the development of Monoclonal antibodies (mAbs) as
therapeutics as they have shown great promise in the treatment of

serious or untreatable conditions such as cancer. This is partly due to
their highly specific targeting of antigens as well as their high efficacy
and fewer side effects. Vaccines and effective antibody therapeutics
will play an integral role in keeping the on-going COVID-19 pandemic
and emerging variants under control. Neutralizing Antibodies are
an example of molecules that will play a critical role in vaccine and
therapeutics development as they can bind to a virus in a manner
that blocks infection. Neutralizing Antibodies can be isolated from
plasma of convalescent patients and have become a major focus for
researchers around the globe in the race to a better understanding
of the mechanisms of action (MOA) against the receptor-binding
domains (RBD) of the SARS-CoV-2 Spike protein.
In this collection we highlight the research efforts and related
applications utilized to study binding affinity, potency and target
specificities of neutralizing antibodies against SARS-CoV-2 and their
potential for future use against diseases caused by viruses from the
same coronavirus subgroup. The novel findings provide deeper
insights into the immune responses to infection, and help further the
understanding of the interactions between the spike protein on the
SARS-CoV-2 virus and its receptor on host cells. The interruption of
this interaction has become the key target of COVID-19 therapeutics.
Sartorius continues to support these early stage investigations by
providing innovative Incucyte® live-cell analysis and iQue® advanced
flow cytometry and Octet® label-free biomolecular interactions
analysis platforms to provide new critical information, with
confidence, as quickly as possible.
Learn more at -
Monoclonal Antibody Discovery and Development | Sartorius



Table of Contents for the Digital Edition of Sartorius_May21_NeutAntiMakingTheir

Sartorius_May21_NeutAntiMakingTheir - 1
Sartorius_May21_NeutAntiMakingTheir - 2
Sartorius_May21_NeutAntiMakingTheir - 3
Sartorius_May21_NeutAntiMakingTheir - Contents
Sartorius_May21_NeutAntiMakingTheir - 5
Sartorius_May21_NeutAntiMakingTheir - 6
Sartorius_May21_NeutAntiMakingTheir - 7
Sartorius_May21_NeutAntiMakingTheir - 8
Sartorius_May21_NeutAntiMakingTheir - 9
Sartorius_May21_NeutAntiMakingTheir - 10
Sartorius_May21_NeutAntiMakingTheir - 11
Sartorius_May21_NeutAntiMakingTheir - 12
Sartorius_May21_NeutAntiMakingTheir - 13
Sartorius_May21_NeutAntiMakingTheir - 14
Sartorius_May21_NeutAntiMakingTheir - 15
Sartorius_May21_NeutAntiMakingTheir - 16
Sartorius_May21_NeutAntiMakingTheir - 17
Sartorius_May21_NeutAntiMakingTheir - 18
Sartorius_May21_NeutAntiMakingTheir - 19
Sartorius_May21_NeutAntiMakingTheir - 20
Sartorius_May21_NeutAntiMakingTheir - 21
Sartorius_May21_NeutAntiMakingTheir - 22
Sartorius_May21_NeutAntiMakingTheir - 23
Sartorius_May21_NeutAntiMakingTheir - 24
Sartorius_May21_NeutAntiMakingTheir - 25
Sartorius_May21_NeutAntiMakingTheir - 26
Sartorius_May21_NeutAntiMakingTheir - 27
Sartorius_May21_NeutAntiMakingTheir - 28
Sartorius_May21_NeutAntiMakingTheir - 29
Sartorius_May21_NeutAntiMakingTheir - 30
Sartorius_May21_NeutAntiMakingTheir - 31
Sartorius_May21_NeutAntiMakingTheir - 32
Sartorius_May21_NeutAntiMakingTheir - 33
Sartorius_May21_NeutAntiMakingTheir - 34
Sartorius_May21_NeutAntiMakingTheir - 35
Sartorius_May21_NeutAntiMakingTheir - 36
Sartorius_May21_NeutAntiMakingTheir - 37
Sartorius_May21_NeutAntiMakingTheir - 38
Sartorius_May21_NeutAntiMakingTheir - 39
Sartorius_May21_NeutAntiMakingTheir - 40
Sartorius_May21_NeutAntiMakingTheir - 41
Sartorius_May21_NeutAntiMakingTheir - 42